LUPRON DEPOT-PED KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5480656 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5643607 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5716640 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5575987 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5631020 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US6036976 | ABBVIE ENDOCRINE INC | Sustained release microspheres and preparation thereof |
Dec, 2016
(7 years ago) | |
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(3 years from now) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
Lupron Depot-Ped Kit is owned by Abbvie Endocrine Inc.
Lupron Depot-Ped Kit contains Leuprolide Acetate.
Lupron Depot-Ped Kit has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Lupron Depot-Ped Kit are:
- US5480656
- US5643607
- US5716640
- US5575987
- US6036976
- US5631020
Lupron Depot-Ped Kit was authorised for market use on 16 April, 1993.
Lupron Depot-Ped Kit is available in powder;intramuscular dosage forms.
Lupron Depot-Ped Kit can be used as treatment of pediatric patients with central precocious puberty.
The generics of Lupron Depot-Ped Kit are possible to be released after 05 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 14, 2026 |
| M(M-107) | Oct 08, 2014 |
| New Product(NP) | Aug 15, 2014 |
Drugs and Companies using
LEUPROLIDE ACETATE ingredient
Market Authorisation Date:
16 April, 1993Treatment:
Treatment of pediatric patients with central precocious pubertyDosage:
More Information on Dosage
LUPRON DEPOT-PED KIT family patents
